DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/9e1968/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Canada" report to their offering.
The Canadian pharmaceutical market is projected to grow at a relatively fast rate in the coming years, strengthened by an increasing demand for pharmaceuticals, due to an aging population and a commitment to a high standard of healthcare provision. However, due to the economic recession, public finances are set to deteriorate for the first time in a decade, and spending constraints could affect future expenditure on healthcare.
Patented drug prices in Canada are controlled by the government via the Patented Medicine Prices Review Board (PMPRB), and tend to be considerably lower than in the USA. This continues to irk the branded industry, and has led to a burgeoning parallel trade between the two countries. However, the future of the practice is uncertain.
In 2010, Canada remains on the USTRs Priority Watch List over concerns with IPR protection and enforcement. Canada's patent laws have been progressively tightened since the 1980s. A focus for debate is the process of evergreening, which generic companies have strongly lobbied against. Government amendments in 2006 attempted to offer a balanced reform but were poorly received by the local generic industry.
In July 2010, British Columbia announced it is to cut the prices of generics from an average of 65% of the brand-name price to around 35% over a three-year period. The province is the latest to cut the price of generic drugs in Canada. In April 2010, Ontario announced plans to cut the price of generics to 25% of the cost of the brand-name originator, while the Quebec Health Minister, Yves Bolduc, announced in July 2010 that Quebec would implement a similar cut to Ontario, since its regulations require it to pay the lowest generic prices available in Canada.
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Key Topics Covered:
- Highly Detailed Report Content
- Executive Summary
- Regulatory Affairs
- Pricing & Reimbursement
- Distribution Channels
- Market Analysis
- OTC Pharmaceuticals
- Generic Pharmaceuticals
- Biologics & Biosimilars
- Opportunities & Challenges
- Methodology & Sources
- Abbott Laboratories Ltd
- Aventis Pharma (sanofi-aventis)
- Cangene Corporation
- Draxis Health
- Genpharm Inc
- GlaxoSmithKline (GSK)
- Merck Frosst & Co
- Novartis Pharmaceuticals Canada Inc
- Novopharm Ltd (Teva)
- Pfizer Canada Inc
- Ranbaxy Canada
- Schering Canada Inc
For more information visit http://www.researchandmarkets.com/research/9e1968/the_pharmaceutical
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: North America Canada
INDUSTRY KEYWORDS: Health Pharmaceutical